Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 28, 2021

Lenvatinib With or Without Everolimus in Patients With Metastatic RCC After ICI and VEGFR-TKI Therapies

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Lenvatinib With or Without Everolimus in Patients With Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and VEGFR-TKI Therapies
Oncologist 2021 Mar 31;[EPub Ahead of Print], AJ Wiele, TK Bathala, AW Hahn, L Xiao, M Duran, JA Ross, E Jonasch, AY Shah, MT Campbell, P Msaouel, NM Tannir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading